AUSTRIA: BAXTER EXPANDS IMMUNO

Article Abstract:

The Immuno Hyland division of Baxter is to increase R&D investment in Austria in 1999. In 1998 the spending amounted to Sch 660mn, which is about 15% of Baxter's overall R&D budget. R&D in Austria concerns mainly the development of blood plasma products, biotechnological (recombinant) drugs and vaccines. (The Hyland Immuno division produces also wound care products.) The Austrian company that has been renamed Baxter AG expects a 20% increase in turnover in year 2000. In 1998 sales amounted to Sch 4.9bn, to which exports contributed 90%. Since it took over Immuno in 1997, Baxter has increased the number of staff at the Austrian company by 200 to 2,000. It is planning to hire up to 250 people in the next two years. From year 2000 the Baxter group is to launch two new products per year.

Comment:

Austrian co.

Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Pharmaceutical Preparation Manufacturing, Ethical Preparations, Baxter AG

---

AUSTRIA: NOVARTIS BOOSTING RESEARCH

Article Abstract:

Novartis is expanding its research facilities in Vienna by setting up an antibiotics research centre for generic drugs in 2001. The new facility will have about 50 staff and an annual budget of Sch 100mn. The Swiss chemicals group has already concentrated its research into dermatology and immunology in the Austrian capital. Just under 600 of the 2,560 Novartis staff in Austria are involved in research and development. With spending of more than Sch 1.2bn, the company runs Austria's biggest private laboratory. Novartis Austria expects a double-digit increase in turnover in year 2001. Last year the company saw a 15% increase in sales to Sch 13.4bn, to which Sch 10.8bn was contributed by Kundl-based Biochemie GmbH.

Biological products exc. diagnostic

---

AUSTRIA: IMPROVEMENT FOR NOVARTIS

Article Abstract:

The Austrian subsidiary of Novartis increased turnover by 6.4% to Sch 12.2bn in 1999, and further growth is planned for 2000. Novartis is to focus on innovative medicines and is to launch new preparations for asthma, wound treatment and hormone therapy. In the food sector, Novartis is to launch the functional food brand Aviva.

Food Manufacturing, FOOD AND KINDRED PRODUCTS, Health Foods, Novartis AG

Similar abstracts:

• Abstracts: AUSTRIA: CHANGE AT ENBW. AUSTRIA: NEW CLIENTS FOR GERMAN AMPERE. AUSTRIA: TOUGH MARKET FOR FOREIGN POWER FIRMS
• Abstracts: AUSTRIA: PIZZA HUT'S EXPANSION PLANS. AUSTRIA: BURGER KING'S RETURN. AUSTRIA: AMBITIOUS PLANS OF PIZZA HUT
• Abstracts: AUSTRIA: WINTER TYRES TESTED. JAPAN/AUSTRIA: NEW BRIDGESTONE MOTORBIKE TYRES. AUSTRIA: QUALITY RANKING OF TYRES

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.